FTSE 100 news / Companies and sectors / AstraZeneca / Citi raises AstraZeneca target to £186

Citi raises AstraZeneca target to £186

+10.0 strongly positive

Citi raised its AstraZeneca target to £186 on improved tozorakimab prospects and clinical data.

4 headlines from 3 outlets, from 7 October 2026 to 8 October 2026. The story's tone is the average of its headlines' own scores.

How each outlet covered it

Average tone of each outlet's headlines in this story. One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Outlet	Headlines	Tone
Pluang	2	+10.0
Proactive financial news	1	+10.0
AD HOC NEWS	1	+8.3

Day by day

Thursday 8 October 2026 1 headline

Citi raised its target to 18,600p.

+8.3 Citi raises target for AstraZeneca stock to GBp 18,600 AD HOC NEWS
Citi raises price target

Wednesday 7 October 2026 3 headlines

Citi raised its AstraZeneca target to £186 on improved tozorakimab prospects and clinical data.

+10.0 Citi raises AstraZeneca target to £186 as tozorakimab prospects improve Proactive financial news
Citi target raised as tozorakimab prospects improve
+10.0 Citi raises AstraZeneca target price to £186 on improved drug prospects and strong clinical data Pluang
Citi raises target to £186 on strong data
+10.0 Citigroup raises AstraZeneca price target after strong clinical trial results Pluang
Citigroup raises target on strong trial results

AstraZeneca: all news analysis · Sector · FTSE 100 news